Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
Research and Practice in Thrombosis and Haemostasis(2023)
Abstract
•Data regarding maintenance of immune tolerance in patients treated with emicizumab are scarce.•Patients with hemophilia A and FVIII inhibitors who initiated emicizumab were followed up for 3 years.•No inhibitor recurrence was noted among fully tolerized patients.•Successfully tolerized patients with hemophilia A treated with emicizumab did not lose tolerance.
MoreTranslated text
Key words
viii,emicizumab,inhibitors
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined